~~<i id='CAFB299127'><strike id='CAFB299127'><tt id='CAFB299127'><pre id='CAFB299127'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：focus 2025-09-28 01:36:48 - browse：6651

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Juul spent big to court Black leaders to promote its e

focus

explore

entertainment

Wikipedia

hotspot

explore

AdobeNotsolongago,afatherbrokedownintearswithmeoverZoom—tearsofrelief.Whenthisfatherhadreceivedtestr

WSS

Medicare drug price negotiation’s day in court

'Screen and refer' systems are hurting patients

Apple Vision Pro: A first look at health apps on the new VR headset

AstraZeneca lung cancer study comes in below expectations

Vertigo drug brings hope for rare neuron disorder, Niemann

Use doctors trained outside the U.S. to ease the physician shortage

hotspot

knowledge

focus

Tori Bowie and the unacceptable rates of Black maternal death

Congressmen charge Covid hearing ‘could have been an email’

Peter Hotez and the public health issue of online harassment

Cognito secures funding to test medical device for Alzheimer's

Activists slam private health insurers over coverage restrictions

Vertigo drug brings hope for rare neuron disorder, Niemann

Psychedelics group wrestles with new pharma identity

New Ultima Genomics DNA sequencer can read genome for $100

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT wants to know your pick for a great summer read or listen

explore

How Robert F. Kennedy Jr. distorted vaccine science

A $475,000 price tag for a new cancer drug: crazy or meh?

FDA drug safety: Singulair case shows systemic surveillance flaws

Cognito secures funding to test medical device for Alzheimer's

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

New Ultima Genomics DNA sequencer can read genome for $100

entertainment

Wikipedia

hotspot

explore